Glassia is a prescription drug approved by the Food and Drug Administration (FDA) as maintenance therapy in adults who have clinically evident emphysema due to Alpha-1 antitrypsin deficiency, a rare genetic condition. Glassia is also known by its drug name, alpha1-proteinase inhibitor [human].
Glassia is an alpha1-proteinase inhibitor, a type of molecule derived from human plasma. Glassia is believed to work by protecting the lungs from damage.
How do I take it?
Glassia is administered once a week as an intravenous infusion.
Glassia comes in the form of a single-use vial.
The FDA-approved label for Glassia lists common side effects including headache and upper respiratory tract infections.
Rare but serious side effects listed for Glassia can include severe allergic reactions and the potential risk for transmitting infectious agents such as viruses.
For more details about this treatment, visit:
Glassia – Shire